Dusa A - Search Results

1

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA, Constantinescu SN. Dusa A, et al. J Biol Chem. 2008 May 9;283(19):12941-8. doi: 10.1074/jbc.M709302200. Epub 2008 Mar 6. J Biol Chem. 2008. PMID: 18326042 Free article.

2

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. Dusa A, et al. PLoS One. 2010 Jun 16;5(6):e11157. doi: 10.1371/journal.pone.0011157. PLoS One. 2010. PMID: 20585391 Free PMC article.

3

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.

Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y, Defour JP, Dusa A, Besancenot R, Giraudier S, Villeval JL, Knoops L, Courtoy PJ, Vainchenker W, Constantinescu SN. Pecquet C, et al. Among authors: dusa a. Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29. Blood. 2012. PMID: 22378845 Free article.

4

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.

Constantinescu SN, Leroy E, Gryshkova V, Pecquet C, Dusa A. Constantinescu SN, et al. Among authors: dusa a. Biochem Soc Trans. 2013 Aug;41(4):1048-54. doi: 10.1042/BST20130084. Biochem Soc Trans. 2013. PMID: 23863177 Review.

5

Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

Leroy E, Balligand T, Pecquet C, Mouton C, Colau D, Shiau AK, Dusa A, Constantinescu SN. Leroy E, et al. Among authors: dusa a. J Allergy Clin Immunol. 2019 Jul;144(1):224-235. doi: 10.1016/j.jaci.2018.12.1023. Epub 2019 Jan 29. J Allergy Clin Immunol. 2019. PMID: 30707971

6

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.

Hornakova T, Springuel L, Devreux J, Dusa A, Constantinescu SN, Knoops L, Renauld JC. Hornakova T, et al. Among authors: dusa a. Haematologica. 2011 Jun;96(6):845-53. doi: 10.3324/haematol.2010.036350. Epub 2011 Mar 10. Haematologica. 2011. PMID: 21393331 Free PMC article.

7

Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.

Leroy E, Dusa A, Colau D, Motamedi A, Cahu X, Mouton C, Huang LJ, Shiau AK, Constantinescu SN. Leroy E, et al. Among authors: dusa a. Biochem J. 2016 Jun 1;473(11):1579-91. doi: 10.1042/BCJ20160085. Epub 2016 Mar 30. Biochem J. 2016. PMID: 27029346 Free PMC article.

8

JAK2, the JAK2 V617F mutant and cytokine receptors.

Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN. Staerk J, et al. Among authors: dusa a. Pathol Biol (Paris). 2007 Mar;55(2):88-91. doi: 10.1016/j.patbio.2006.06.003. Epub 2006 Aug 14. Pathol Biol (Paris). 2007. PMID: 16904848 Review.

9

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

Vainchenker W, Dusa A, Constantinescu SN. Vainchenker W, et al. Among authors: dusa a. Semin Cell Dev Biol. 2008 Aug;19(4):385-93. doi: 10.1016/j.semcdb.2008.07.002. Epub 2008 Jul 17. Semin Cell Dev Biol. 2008. PMID: 18682296 Review.

10

Impact of isolated germline JAK2V617I mutation on human hematopoiesis.

Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, Burns A, Score J, Rugless M, Clifford R, Moule S, Bienz N, Vyas P, Cross N, Gale RE, Henderson S, Constantinescu SN, Schuh A, Jacobsen SE. Mead AJ, et al. Among authors: dusa a. Blood. 2013 May 16;121(20):4156-65. doi: 10.1182/blood-2012-05-430926. Epub 2013 Mar 27. Blood. 2013. PMID: 23535062 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page